Navigation Links
Avicena Announces Positive Phase II Data for a Combination Trial Involving AL-08 for the Treatment of Amyotrophic Lateral Sclerosis (ALS)
Date:12/3/2007

ference in the ALS- Functional Score between the therapies tested was large enough, and comparison to the historical controls was non-futile at the 6-month time point, we were able to finish the trial early after just 60 patients," stated Dr. Gordon. "We originally planned to enroll up to 120 patients, in sequential pools of 60. Our ability to halt the trial early underscores the potential efficacy of AL-08, which can be further evaluated in a Phase III ALS clinical trial."

"We are pleased that AL-08/celecoxib slowed deterioration in ALS- Functional Score compared to the other treatment and believe that results of this trial highlight the potential of this combination treatment for ALS patients," stated Belinda Tsao Nivaggioli, CEO and Chairman of Avicena. "We are eager to proceed with designing our Phase III clinical trial which will attempt to confirm the efficacy of AL-08".

About the Trial

The randomized, double-blind, selection trial targeted enrollment of up to 120 patients in sequential pools of 60 to evaluate the neuroprotective capacity of two drug combinations, AL-08/ minocycline and AL-08/celecoxib. The trial used a group sequential design and a natural history control group for a futility analysis. The primary objective was treatment selection based on which drug combination appeared to slow deterioration in the ALS-Functional Score.

Patients were randomized to receive daily administration of AL- 08/minocycline or AL-08/celecoxib. The trial was stopped early after the first pool of 60 patients when the selection criteria was met by showing a large enough difference in ALS-Functional Score between the two treatment arms.

Results showed that patients treated with AL-08/celcoxib showed a smaller mean functional decline versus AL-08/minocycline. At the end of the trial, the decline in ALS-Functional Score in both treatment arms was compared separately to the mean historical control group at a 0.05 significance level. The mea
'/>"/>

SOURCE Avicena Group, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Avicena Scientific Collaborator Advances Program for Using Energy Enhancing Molecules to Treat Neuromuscular Diseases
2. Survival Data for Avicenas Amyotrophic Lateral Sclerosis Drug Candidate, AL-02, to be Presented at 18th International Symposium on ALS/MND
3. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
4. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
5. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
6. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
7. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
8. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
9. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
10. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
11. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Tegra Medical is very pleased to announce the appointment of ... Executive Officer.  Mark was promoted from his current role of ... four facilities in Massachusetts , ... Medical in 2012 with 20+ years of broad-based operations, sales, ...
(Date:1/15/2014)... NEW YORK , Jan. 15, 2014 ... research report is available in its catalogue: ... & Forecast – Worldwide Analysis ... Pump Market Analysis ...
(Date:1/15/2014)... Jan. 15, 2014  Zafgen, Inc., a leading biopharmaceutical ... severely obese patients, today announced initial results from ... inhibitor of methionine aminopeptidase 2 (MetAP2), in patients ... genetic obesity.  These results showed improvements in body ...
Breaking Medicine Technology:Tegra Medical Appoints New Chief Executive Officer 2Tegra Medical Appoints New Chief Executive Officer 3Insulin Pump Market & Forecast - Worldwide Analysis 2Insulin Pump Market & Forecast - Worldwide Analysis 3Insulin Pump Market & Forecast - Worldwide Analysis 4Insulin Pump Market & Forecast - Worldwide Analysis 5Insulin Pump Market & Forecast - Worldwide Analysis 6Insulin Pump Market & Forecast - Worldwide Analysis 7Insulin Pump Market & Forecast - Worldwide Analysis 8Insulin Pump Market & Forecast - Worldwide Analysis 9Insulin Pump Market & Forecast - Worldwide Analysis 10Insulin Pump Market & Forecast - Worldwide Analysis 11Insulin Pump Market & Forecast - Worldwide Analysis 12Insulin Pump Market & Forecast - Worldwide Analysis 13Insulin Pump Market & Forecast - Worldwide Analysis 14Insulin Pump Market & Forecast - Worldwide Analysis 15Insulin Pump Market & Forecast - Worldwide Analysis 16Insulin Pump Market & Forecast - Worldwide Analysis 17Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4
... OXNARD, Calif., March 30, 2011 HealthSport, Inc. (OTC ... formulator, developer and manufacturer of dissolvable bi-layer oral thin ... ingredients through buccal absorption, announced today it has signed ... assets of SMI Manufacturing from RT Holdings, LLC.  HealthSport,s ...
... FHI has been selected as one of six ... consortium of 14 global health Product Development Partnerships (PDPs). ... deliver affordable treatments and vaccines that will help improve ... people. FHI,s forty years of research experience ...
Cached Medicine Technology:HealthSport Signs Letter of Intent to Acquire "Excellent" Rated cGMP Certified Nutraceutical Manufacturing Plant 2HealthSport Signs Letter of Intent to Acquire "Excellent" Rated cGMP Certified Nutraceutical Manufacturing Plant 3FHI Selected as Preferred Provider to a Consortium of Product Development Partnerships 2
(Date:4/18/2014)... University psychologists have made a brain-related discovery that ... disorders. , This discovery opens up the possibility ... suppress a specific brain activity that the researchers ... The Journal of Neuroscience has just ... McDonald, an associate professor of psychology and his ...
(Date:4/17/2014)... non-cancerous prostate tissue may have nearly twice the risk ... inflammation, according to results of a new study led ... , The link between persistent inflammation and cancer was ... those with a Gleason score between 7 and ... and rapidly growing prostate cancers. , "What we,ve shown ...
(Date:4/17/2014)... April issue of Experimental Biology and Medicine ... Rex Gaskins and Paul Kenis in the Institute ... the University of Illinois Urbana-Champaign describe their recent ... underlie a variety of cell functions including energy ... crucial roles in regulating normal cellular behavior, redox ...
(Date:4/17/2014)... A Northwestern University synthetic biology team has created ... create programmable therapeutics that could travel the body ... disease. , Engineering cell-based, biological devices that monitor ... in clinical synthetic biology. However, no existing technology ... a patient,s physiological state and respond in a ...
(Date:4/17/2014)... IL, April 17, 2014-- Colic affects about one in ... for numerous pediatric visits during the first several months ... colic symptoms was showing promise; however, the April 1, ... (BMJ2014;348:g2107; Sung, Valerie) reported on a study, "Probiotics and ... L reuteri for infant colic did ...
Breaking Medicine News(10 mins):Health News:Scientists discover brain's anti-distraction system 2Health News:Chronic inflammation linked to 'high-grade' prostate cancer 2Health News:Chronic inflammation linked to 'high-grade' prostate cancer 3Health News:Live cell imaging reveals distinct alterations of subcellular glutathione potentials 2Health News:Building 'smart' cell-based therapies 2Health News:New study says probiotic use for infant colic is not effective in reducing symptoms 2
... Drink wine and live longer? For,generations, red wine, ... life in the Gers region of southwestern France. The ... offers an explanation,as to why the people of the ... are healthier than others. To view the Multimedia ...
... "Parents need to know,what Planned Parenthood has ... is,an excellent starting point," said Jim Sedlak, vice ... Normal, is obscene and offensive to,Christians.", To ... , American Life League,s second video report ...
... for ulcers and even amputation, researchers say , MONDAY, Nov. ... the wrong size of shoes can put diabetics at risk ... researchers say. , The study, by a team at the ... 89, who had their feet examined and measured while they ...
... The use of a pedometer and a Web site that ... people with diabetes who participated in a recent walking study ... and VA Ann Arbor Healthcare System. The study also suggests ... others. , All participants in the study wore pedometers and ...
... of the most harmful strains of human papillomavirus is ... The vaccine, called nine-valent, is being compared with Gardasil, ... against the two most deadly HPV types. , Were ... vaccine, says Dr. Daron Ferris, family medicine physician and ...
... that in cell cultures, the stress hormone norepinephrine appears ... cells to grow and spread. , The finding, ... progression and spread of some cancers enough so that ... work. , The study also showed that stress ...
Cached Medicine News:Health News:Photos: Drink Wine and Live Longer - '1907' Madiran and Plaimont Wines of Southwest France Sponsor the Launch of The Red Wine Diet 2Health News:Video: American Life League Releases Video Report on Children's Sex Book 2Health News:Ill-Fitting Shoes a Danger to Diabetics 2Health News:Pedometers motivate people with diabetes to walk more 2Health News:Pedometers motivate people with diabetes to walk more 3Health News:New HPV vaccine under study 2Health News:Stress hormone may hasten the progression of certain blood cancers 2Health News:Stress hormone may hasten the progression of certain blood cancers 3
Medtronic, Inc., a world leader in therapies for restoring people with chronic conditions to full life, introduces the AT500 Pacing System for the management of atrial tachyarrhythmias and bradycardi...
The first-ever pacemaker to include Managed Ventricular Pacing (MVP), the EnRhythm Pacing System promotes intrinsic conduction and is clinically proven to significantly reduce unnecessary right ventr...
... System 3000Dx (GCS3000Dx) is the first microarray ... system consists of the FS450Dx Fluidics Station ... the array, the GCS3000Dx Scanner with AutoLoader ... microarrays to be scanned without operator intervention, ...
... EUB-2000 is a compact system capable ... This unit features intuitive operation, high ... membrane style keyboard incorporates an alphanumeric ... mode changes, and toggle keys for ...
Medicine Products: